抗血管生成治疗在食管癌放疗中的应用

doi:10.3760/cma.j.issn.1673-422X.2017.06.017

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (6): 468-.doi: 10.3760/cma.j.issn.1673-422X.2017.06.017

抗血管生成治疗在食管癌放疗中的应用

封悦，于静萍，汪建林

213003 常州，南京医科大学附属常州第二人民医院放疗科

出版日期:2017-06-08 发布日期:2017-06-16
通讯作者: 于静萍 E-mail: yujingping@sina.com
基金资助:
常州市高层次卫生人才培养计划（2016C2BJ007）；常州市科技支撑社会发展项目(CE20125021、CE20165024)；常州市科技局应用基础研究项目（CJ20159050）；江苏省卫生厅指导性科研项目(Z201220)；常州市卫生局重大项目(ZD201105)

Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer

Feng Yue, Yu Jingping, Wang Jianlin

Department of Radiation Oncology, Changzhou Second People′s Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China

Online:2017-06-08 Published:2017-06-16
Contact: Yu Jingping E-mail: yujingping@sina.com
Supported by:
Changzhou HighLevel Health Personnel Training Program (2016C2BJ007); Changzhou Scientific and Technological Support Social Development Project (CE20125021， CE20165024); Changzhou Municipal Science and Technology Bureau Basic Research Project (CJ20159050); Jiangsu Province Health Department Guided Research Project (Z201220); Changzhou Health Bureau Major Project (ZD201105)

摘要/Abstract

摘要： 放疗是食管癌非手术治疗的重要手段，5年生存率仅维持在20%～40%。近年来研究发现，抗血管生成治疗不仅可以直接抑制肿瘤的营养摄取，还可以通过使肿瘤血管正常化改善肿瘤组织的乏氧状态从而增强肿瘤细胞的放射敏感性，有望成为提高食管癌放疗疗效的有效方法。

关键词: 食管肿瘤, 放射疗法, 血管生成抑制剂

Abstract: Radiotherapy is the principle method of nonsurgical treatment for esophageal cancer. The 5year survival rate ranges from 20% to 40%. In recent years, the studies have found that antiangiogenesis therapy can not only directly inhibit tumor nutritional intake, but also turn around tumor hypoxia by normalizing tumor vessels so as to enhance the radiosensitivity of tumor cells, which is expected to become an effective way to improve the curative effect of esophageal cancer radiotherapy.

Key words: Esophageal neoplasms, Radiotherapy, Angiogenesis inhibitors

封悦，于静萍，汪建林. 抗血管生成治疗在食管癌放疗中的应用[J]. 国际肿瘤学杂志, 2017, 44(6): 468-.

Feng Yue, Yu Jingping, Wang Jianlin. Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer[J]. Journal of International Oncology, 2017, 44(6): 468-.

参考文献

［1］ Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelia growth factor expression in patients with esophageal cancer: a systematic review and metaanalysis［J］. Cancer Epidemiol Biomarkers Prev, 2012, 21(7): 1126-1134. DOI: 10.1158/10559965.EPI120020. ［2］ Yu JP, Lu WB, Wang JL, et al. Pathologic response during chemoradiotherapy and variation of serum VEGF levels could predict effects of chemoradiotherapy in patients with esophageal cancer［J］. Asian Pac J Cancer Prev, 2015, 16(3): 1111-1116. ［3］ Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase Ⅰ trial in rectal cancer patients［J］. J Clin Oncol, 2005, 23(31): 8136-8139. ［4］ Ku GY, Bains MS, Park DJ, et al. Phase Ⅱ study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma［J］. J Gastrointest Oncol, 2016, 7(6): 828-837. DOI: 10.21037/jgo.2016.08.09. ［5］ Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial［J］. Lancet, 2014, 383(9911): 31-39. DOI: 10.1016/s01406736(13)617195．［6］ McLarnon A. 2014 Gastrointestinal Cancers Symposium［J］. Lancet Oncol, 2014, 15(3): 262. DOI: 10.1016/s14702045(13)703401. ［7］孙志强, 于静萍, 张志明, 等. 重组人血管内皮抑素对食管癌细胞的放射增敏作用及其机制［J］. 中华放射医学与防护杂志, 2013, 33(4): 346-350. DOI: 10.3760/cma.j.issn.02545098.2013.04.003. ［8］ Jiang Y, Xu W. Effect of endostar combined with radiation therapy for esophageal squamous cell carcinoma on blood perfusion and early efficacy［J］. Int J Radiat Oncol Biol Phys, 2016, 96(2S): E217. DOI: 10.1016/j.ijrobp.2016.06.1135. ［9］ Zhong Z, Gu X, Zhang Z, et al. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus［J］. Br J Radiol, 2012, 85(1019): e1104-e1109. DOI: 10.1259/bjr/15321801. ［10］ Ding YQ, Zhu HC, Chen XC, et al. Sunitinib modulates the radiosensitivity of esophageal squamous cell carcinoma cells in vitro［J］. Dis Esophagus, 2016, 29(8): 1144-1151. DOI: 10.1111/dote.12440. ［11］ Kleibeuker EA, Ten Hooven MA, Castricum KC, et al. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction［J］. Cancer Med, 2015, 4(7): 1003-1015. DOI: 10.1002/cam4.441. ［12］ Horgan AM, Darling G, Wong R, et al. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase Ⅱ trial［J］. Dis Esophagus, 2016, 29(8): 1152-1158. DOI: 10.1111/dote.12444. ［13］ Ku GY, Janjigian YY, Shah MA, et al. Phase Ⅱ trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: response and prolonged stable disease observed in adenocarcinoma［J］. J Clin Oncol, 2013, 33(4part2): 848-866. ［14］ Janjigian YY, Vakiani E, Ku GY, et al. Phase Ⅱ trial of Sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer［J］. PLoS One, 2015, 10(8): e0134731. DOI: 10.1371/journal.pone.0134731. ［15］ Zhang H. Apatinib for molecular targeted therapy in tumor［J］. Drug Des Devel Ther, 2015, 9: 6075-6081. DOI: 10.2147/DDDT.S97235. ［16］ Ding J, Chen X, Dai X, et al. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatographytandem mass spectrometry and its application to a pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 895896: 108-115. DOI: 10.1016/j.jchromb.2012.03.027. ［17］ Li J, Qin S, Xu J, et al. Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebocontrolled, parallelarm, phase Ⅱ trial［J］. J Clin Oncol, 2013, 31(26): 3219-3225. DOI: 10.1200/jco.2013.48.8585. ［18］ Li J, Qin S, Xu J, et al. O0029 phase Ⅲ study of apatinib in advanecd gastric cancer: a randomized, doubleblind, placebocontrolled trial［J］. J Clin Oncol, 2014, 25(suppl 2): ii117. DOI: 10.1093/annonc/mdu193.29. ［19］ Pavlakis N, Sjoquist KM, Tsobanis E, et al. LBA06 INTEGRATE: a randomized phase Ⅱ doubleblind placebocontrolled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC)—a study by the Australasian Gastrointestinal Trials Group (AGITG): final overall and subgroup results［J］. Ann Oncol, 2015, 26(suppl 4): iv119. DOI: 10.1093/annonc/mdv262.06. ［20］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 303-312. DOI: 10.1016/s01406736(12)61900x. ［21］ Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 295-302. DOI: 10.1016/s01406736(12)618571. ［22］ Yu J, Liu F, Sun M, et al. Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinomacells by tetrandrine［J］. Cancer Biother Radiopharm, 2011, 26(4): 437-442. DOI: 10.1089/cbr.2011.0964. ［23］ Yu JP, Sun SP, Sun ZQ, et al. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer［J］. World J Gastroenterol, 2014, 20(17): 5098-5103. DOI: 10.3748/wjg.v20.i17.5098.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[11]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[12]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[13]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[14]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[15]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.

抗血管生成治疗在食管癌放疗中的应用

Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价